Fenebrutinib Shows Promise in MS Trial Results

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2199049

Show notes

Roches experimental MS pill, fenebrutinib, shows promising results in late-stage trials, reducing relapses and slowing disability progression in both relapsing and primary progressive MS. The drug outperformed teriflunomide and held its ground against OCREVUS, Roches approved therapy. Roche shares surged, and the company plans to submit all data for regulatory approval in the first half of 2026.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.